| Systematic (IUPAC) name | |
|---|---|
| 5-Fluoro-1-[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-pyrimidine-2,4-dione | |
| Clinical data | |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a682006 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 50-91-9 |
| ATC code | None |
| PubChem | CID 5790 |
| DrugBank | APRD00692 |
| ChemSpider | 5586 |
| UNII | 039LU44I5M |
| KEGG | D04197 |
| ChEBI | CHEBI:60761 |
| ChEMBL | CHEMBL917 |
| Chemical data | |
| Formula | C9H11FN2O5 |
| Mol. mass | 246.192 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Floxuridine (also 5-fluorodeoxyuridine) is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer.
Contents |
Floxuridine, an analog of 5-fluorouracil, is a fluorinated pyrimidine.
Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.
Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-fluorouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to F H Faulding, which became Mayne Pharma.
In the US the drug is supplied by APP Pharmaceuticals, LLC; Hospira, Inc.; and Bedford Laboratories.